Inventor
FINKELSTEIN NINA
IL27 patents
⚠️ This page may combine multiple inventors who share the name “FINKELSTEIN NINA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TEVA PHARMA
25 patentsUS7060833B2Jun 13, 2006
Substantially pure cilostazol and processing for making same
TEVA PHARMA11 citations92
US6515128B2Feb 4, 2003
Processes for preparing cilostazol
TEVA PHARMA20 citations92
US6281381B1Aug 28, 2001
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
TEVA PHARMA18 citations92
US5646188AJul 8, 1997
Polyamine derivatives of 1-aminoindan
TEVA PHARMA46 citations91
US6825214B2Nov 30, 2004
Substantially pure cilostazol and processes for making same
TEVA PHARMA11 citations82
US6963008B2Nov 8, 2005
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
TEVA PHARMA8 citations74
US6696601B2Feb 24, 2004
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
TEVA PHARMA11 citations74
US7067669B2Jun 27, 2006
Substantially pure cilostazol and processes for making same
TEVA PHARMA5 citations73
US7064208B2Jun 20, 2006
Substantially pure cilostazol and processes for making same
TEVA PHARMA5 citations73
US6909004B2Jun 21, 2005
Method for the purification of lansoprazole
TEVA PHARMA5 citations73
US7692008B2Apr 6, 2010
Reference standard for characterization of rosuvastatin
TEVA PHARMA2 citations62
US7692010B2Apr 6, 2010
Reference standard for characterization of rosuvastatin
TEVA PHARMA2 citations62
US7692009B2Apr 6, 2010
Reference standard for characterization of rosuvastatin
TEVA PHARMA2 citations62
US7244844B2Jul 17, 2007
Reference standard for characterization of rosuvastatin
TEVA PHARMA2 citations62
US7060837B2Jun 13, 2006
Method for the purification of lansoprazole
TEVA PHARMA3 citations62
US7022859B2Apr 4, 2006
Method for the purification of lansoprazole
TEVA PHARMA2 citations62
US6777554B2Aug 17, 2004
Preparation of N-methylparoxetine and related intermediate compounds
TEVA PHARMA3 citations62
US6576764B2Jun 10, 2003
Synthesis and crystallization of piperazine ring-containing compounds
TEVA PHARMA2 citations62
US6545149B2Apr 8, 2003
Synthesis and crystallization of piperazine ring-containing compounds
TEVA PHARMA3 citations62
US7507829B2Mar 24, 2009
Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
TEVA PHARMA3 citations60
US7741482B2Jun 22, 2010
Reference standard for characterization of rosuvastatin
TEVA PHARMA0 citations52
US7674923B2Mar 9, 2010
Process for preparing forms of atorvastatin calcium substantially free of impurities
TEVA PHARMA0 citations52
US7622588B2Nov 24, 2009
Method for the purification of lansoprazole
TEVA PHARMA0 citations51
US7915423B2Mar 29, 2011
Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
TEVA PHARMA1 citations50
US7683177B2Mar 23, 2010
Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
TEVA PHARMA0 citations50